相关实验视频

Updated: May 31, 2025

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

通过线粒体转移在瘤微环境中的免疫逃避

Hideki Ikeda^1,2, Katsushige Kawase^1,3, Tatsuya Nishi^4,5

¹Division of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.

|January 22, 2025

概括

癌细胞将突变的线粒体转移到免疫细胞中,从而损害抗瘤反应. 这种线粒体转移是一种新的癌症免疫规避机制,影响患者的预后和免疫疗法的有效性.

科学领域:

免疫学
分子生物学
癌症研究

背景情况:

瘤细胞通过瘤微环境中的复杂机制逃避免疫攻击.
瘤透淋巴细胞 (TIL) 的代谢重编程和线粒体功能障碍阻碍了抗瘤免疫力.
这些免疫规避策略的确切机制尚不完全理解.

研究的目的:

阐明癌细胞逃避T细胞间接攻击的机制.
调查线粒体转移在癌症免疫逃避中的作用.
确定线粒体DNA (mtDNA) 突变在TIL中的功能后果.

主要方法:

对临床瘤样本的分析.
在癌细胞和TIL之间识别共享的mtDNA突变.
评估线粒体转移及其对T细胞功能的体外和体内研究.

主要成果:

在TIL和癌细胞中发现了共享的mtDNA突变.
具有mtDNA突变的线粒体从癌细胞转移到TILs.
转移的线粒体因抑制分子而抵抗线粒体消化,导致同质体替代和T细胞功能障碍.
在TILs中mtDNA突变会损害效应器功能和记忆形成,降低抗瘤免疫力.
在黑色素瘤和非小细胞肺癌中,瘤组织的mtDNA突变预测免疫检查点抑制剂的反应不佳.

结论:

线粒体从癌细胞转移到TIL是一种新的免疫逃避机制.
获得的mtDNA突变会破坏TIL功能并促进瘤的免疫逃逸.
这种途径为开发新的癌症免疫疗法提供了潜在的目标.

更多相关视频

MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells

MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells

Published on: February 22, 2017

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...